ClinicalTrials.gg
CompletedNCT01728623Updated Aug 14, 2020Results posted

A Study of E7080 in Subjects With Advanced Thyroid Cancer

A Phase 2 interventional study of E7080 capsule in Thyroid Cancer, sponsored by Eisai Co., Ltd.. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-08-14.

Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing lenvatinib in Thyroid Neoplasms — 6 open to participants now, 7 under way, none of them phase 3. lenvatinib · Thyroid Neoplasms.

Enrollment
7th of 17
51 · median 35
Started
2012
the only one that year
Phase 2
10 of 17
2 open now
Registered
3rd of 17
by date
Lead sponsor
2 of 17
Eisai Co., Ltd.

Among the 17 studies testing lenvatinib in Thyroid Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2012, is one of 10 in phase 2, and was the 3rd registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

6 of the 17 studies testing lenvatinib in Thyroid Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lenvatinib in Thyroid Neoplasms, or all of them as a file.
02

Study summary

This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally administered once daily (QD) in subjects with advanced thyroid cancer.

03

Conditions studied

  • Thyroid Cancer

Browse trials for

Keywords

  • Thyroid cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologically or clinically diagnosed with thyroid cancer
  2. Performance Status (ECOG-PS) 0-2
  3. Adequate laboratory values/organ function tests

Exclusion criteria

Exclusion criteria

Participants with following complication or disease history

  1. Systemic severe infection
  2. Significant cardiovascular impairment
  3. greater than 480 milliseconds
  4. Active hemoptysis
  5. Bleeding or thrombotic disorders
  6. Having greater than 1+ proteinuria on urine dipstick testing will undergo 24 hour urine collection for quantitative assessment of proteinuria
  7. Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of E7080
  8. Major surgery within 3 weeks before enrollment
  9. With co-existing effusion requiring drainage
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    E7080

    Drug: E7080 capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Only TEAEs are included in the summary. For detailed list of adverse events (AEs), see the AE section. For each participant, only one TEAE in the same category was counted and for multiple TEAEs with different Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grades, only the event with the highest grade was reported. All AEs were graded using CTCAE v 4.0, except for alopecia and infertility.

    Time frame: Screening visit to 30 days after the last dose of study drug, or assessed up to 3 years

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from (1) the date of randomization to the date of first documentation of disease progression based on Investigator and Independent Review Committee assessments according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), or (2) death, whichever came first. Disease progression for the MTC group was measured using computed tomography (CT) or magnetic resonance imaging (MRI) on targeted tumors. Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions. Summarized by the Kaplan-Meier method using median time with 95% confidence interval (CI).

    Time frame: From first date of study treatment until progression of disease or date of death from any cause, whichever comes first, assessed up to 34 months

  2. Overall Survival (OS)

    OS was defined as the time from the date of first dose of study treatment to the date of death from any cause. If death was not observed for a participant, the survival time was censored at the date the participant was last known alive or the data cutoff date (whichever occurred first). Summarized by the Kaplan-Meier method using median time with 95% CI.

    Time frame: From study start until date of death from any cause, assessed up to 34 months

  3. Best Overall Response (BOR)

    BOR was defined as the best response observed between the time of first dose and the study completion, assessed by either of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE). Tumor assessment was performed by the investigator using RECIST 1.1. The CR and PR were determined only when these responses met each criterion even after 28 days from the time observed. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as greater than or equal to 7 weeks for DTC and MTC, greater than or equal to 3 weeks for ATC.

    Time frame: Date of first dose of study treatment to CR, PR, SD, PD, or NE, assessed up to 34 months

  4. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had BOR of CR or PR. Tumor assessment was performed by the investigator using RECIST 1.1. ORR based on the investigator assessment was provided with a corresponding exact 95% CI which was calculated using exact method of binomial distribution.

    Time frame: Date of CR or PR to date of PD or death (whichever was first), assessed up to 34 months

  5. Disease Control Rate (DCR)

    The DCR was defined as the percentage of participants who had BOR of CR, PR, or SD. Tumor assessment was performed by the investigator using RECIST 1.1. DCR based on the investigator assessment was provided with a corresponding exact 95% CI which was calculated using exact method of binomial distribution.

    Time frame: Date of CR, PR, or SD to date of PD or death (whichever was first), assessed up to 34 months

  6. Clinical Benefit Rate (CBR)

    The CBR was defined as the percentage of participants who had BOR of CR, PR, or durable SD (dSD). Tumor assessment was performed by the investigator using RECIST 1.1. Durable stable disease was defined as SD lasting greater than or equal to 23 weeks for DTC and MTC, greater than or equal to 11 weeks for ATC. A 95% CI was calculated using exact method of binomial distribution.

    Time frame: Date of CR, PR, or dSD to date of PD or death (whichever was first), assessed up to 34 months

07

Results

Posted Aug 14, 2020

Participant flow

Participant flow — Overall Study
MilestoneArm 4: Lenvatinib (MTC, DTC, ATC)
Started51
Dtc25
Mtc9
Atc17
Completed23
Not completed28
Withdrew: Disease progression26
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

Only TEAEs are included in the summary. For detailed list of adverse events (AEs), see the AE section. For each participant, only one TEAE in the same category was counted and for multiple TEAEs with different Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grades, only the event with the highest grade was reported. All AEs were graded using CTCAE v 4.0, except for alopecia and infertility.

Time frame:
Screening visit to 30 days after the last dose of study drug, or assessed up to 3 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Percentage of participantsArm 4: Lenvatinib (DTC, MTC, ATC)
TEAEs100.0
CTCAE Grade 3 or 4 TEAEs82.4
Serious TEAEs52.9
TEAEs leading to study drug withdrawal2.0
TEAEs leading to study drug reduction96.1
TEAEs leading to study drug interruption66.7
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from (1) the date of randomization to the date of first documentation of disease progression based on Investigator and Independent Review Committee assessments according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), or (2) death, whichever came first. Disease progression for the MTC group was measured using computed tomography (CT) or magnetic resonance imaging (MRI) on targeted tumors. Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions. Summarized by the Kaplan-Meier method using median time with 95% confidence interval (CI).

Time frame:
From first date of study treatment until progression of disease or date of death from any cause, whichever comes first, assessed up to 34 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsLenvatinib (Arm 1)Lenvatinib (Arm 2)Lenvatinib (Arm 3)
Progression-free Survival (PFS)25.8 (18.4 to NA)9.2 (1.8 to NA)7.4 (1.7 to 12.9)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of first dose of study treatment to the date of death from any cause. If death was not observed for a participant, the survival time was censored at the date the participant was last known alive or the data cutoff date (whichever occurred first). Summarized by the Kaplan-Meier method using median time with 95% CI.

Time frame:
From study start until date of death from any cause, assessed up to 34 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsLenvatinib (Arm 1)Lenvatinib (Arm 2)Lenvatinib (Arm 3)
Overall Survival (OS)31.8 (31.8 to NA)12.1 (3.8 to NA)10.6 (3.8 to 19.8)
SecondaryBest Overall Response (BOR)

BOR was defined as the best response observed between the time of first dose and the study completion, assessed by either of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or not evaluable (NE). Tumor assessment was performed by the investigator using RECIST 1.1. The CR and PR were determined only when these responses met each criterion even after 28 days from the time observed. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as greater than or equal to 7 weeks for DTC and MTC, greater than or equal to 3 weeks for ATC.

Time frame:
Date of first dose of study treatment to CR, PR, SD, PD, or NE, assessed up to 34 months
Reported as:
Number · Percentage of participants
Best Overall Response (BOR)
Percentage of participantsLenvatinib (Arm 1)Lenvatinib (Arm 2)Lenvatinib (Arm 3)
CR000
PR68.022.223.5
SD32.077.870.6
PD005.9
NE000
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had BOR of CR or PR. Tumor assessment was performed by the investigator using RECIST 1.1. ORR based on the investigator assessment was provided with a corresponding exact 95% CI which was calculated using exact method of binomial distribution.

Time frame:
Date of CR or PR to date of PD or death (whichever was first), assessed up to 34 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsLenvatinib (Arm 1)Lenvatinib (Arm 2)Lenvatinib (Arm 3)
Objective Response Rate (ORR)68.0 (46.5 to 85.1)22.2 (2.8 to 60.0)23.5 (6.8 to 49.9)
SecondaryDisease Control Rate (DCR)

The DCR was defined as the percentage of participants who had BOR of CR, PR, or SD. Tumor assessment was performed by the investigator using RECIST 1.1. DCR based on the investigator assessment was provided with a corresponding exact 95% CI which was calculated using exact method of binomial distribution.

Time frame:
Date of CR, PR, or SD to date of PD or death (whichever was first), assessed up to 34 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsLenvatinib (Arm 1)Lenvatinib (Arm 2)Lenvatinib (Arm 3)
Disease Control Rate (DCR)100.0 (86.3 to 100.0)100.0 (66.4 to 100.0)94.1 (71.3 to 99.9)
SecondaryClinical Benefit Rate (CBR)

The CBR was defined as the percentage of participants who had BOR of CR, PR, or durable SD (dSD). Tumor assessment was performed by the investigator using RECIST 1.1. Durable stable disease was defined as SD lasting greater than or equal to 23 weeks for DTC and MTC, greater than or equal to 11 weeks for ATC. A 95% CI was calculated using exact method of binomial distribution.

Time frame:
Date of CR, PR, or dSD to date of PD or death (whichever was first), assessed up to 34 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsLenvatinib (Arm 1)Lenvatinib (Arm 2)Lenvatinib (Arm 3)
Clinical Benefit Rate (CBR)84.0 (63.9 to 95.5)77.8 (40.0 to 97.2)70.6 (44.0 to 89.7)

Adverse events

Collected over AEs were collected for up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 4: Lenvatinib (DTC, MTC, ATC)4/51 (7.8%)27/51 (52.9%)51/51 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventArm 4: Lenvatinib (DTC, MTC, ATC)
Decreased appetiteMetabolism and nutrition disorders7/51
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/51
PneumoniaInfections and infestations3/51
NauseaGastrointestinal disorders2/51
Laryngeal stenosisRespiratory, thoracic and mediastinal disorders2/51
DiarrhoeaGastrointestinal disorders1/51
DysphagiaGastrointestinal disorders1/51
Gastric ulcerGastrointestinal disorders1/51
Haemorrhoidal haemorrhageGastrointestinal disorders1/51
FatigueGeneral disorders1/51
Most frequent other events
Showing 10 of 68
Most frequent other events
EventArm 4: Lenvatinib (DTC, MTC, ATC)
HypertensionVascular disorders46/51
Decreased appetiteMetabolism and nutrition disorders39/51
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders39/51
FatigueGeneral disorders37/51
ProteinuriaRenal and urinary disorders31/51
StomatitisGastrointestinal disorders29/51
DiarrhoeaGastrointestinal disorders27/51
NauseaGastrointestinal disorders21/51
DysphoniaRespiratory, thoracic and mediastinal disorders21/51
ArthralgiaMusculoskeletal and connective tissue disorders19/51

Baseline characteristics

Safety analysis set included all participants who received at least one dose of study drug and had at least one postbaseline safety evaluation.

Age, Continuous
Age, Continuous(years)Lenvatinib (Arm 1)Lenvatinib (Arm 2)Lenvatinib (Arm 3)Total
Mean57.1 ± 12.3460.6 ± 13.7063.4 ± 11.4059.8 ± 12.36
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib (Arm 1)Lenvatinib (Arm 2)Lenvatinib (Arm 3)Total
Female1631130
Male96621
08

Study locations

3 sites
  • Kashiwa, Chiba, Japan
  • Kobe, Hyogo, Japan
  • Koto-ward, Tokyo, Japan
09

References and documents

Publications

  • Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Fukuda N, Sasaki T, Suzuki T, Ikezawa H, Dutcus CE, Tahara M. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 2019 Mar;15(7):717-726. doi: 10.2217/fon-2018-0557. Epub 2019 Jan 14. PubMed 30638399 ↗
  • Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Sasaki T, Suzuki T, Fujino K, Dutcus CE, Takahashi S. Lenvatinib for Anaplastic Thyroid Cancer. Front Oncol. 2017 Mar 1;7:25. doi: 10.3389/fonc.2017.00025. eCollection 2017. PubMed 28299283 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2012 to primary completion in Jul 2015, 34 months.

Results were first posted in Aug 2020, 5 years 1 month after primary completion.

Of 92 phase 2 interventional studies under Thyroid Neoplasms, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Nov 20, 2012
StartActual
Sep 3, 2012
Primary completionActual
Jul 9, 2015
CompletionActual
Oct 1, 2015
Results first posted
Aug 14, 2020
Last update
Aug 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01728623
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Nov 20, 2012
Start date
Sep 3, 2012
Primary completion
Jul 9, 2015
Completion
Oct 1, 2015
Results posted
Aug 14, 2020
Last update
Aug 14, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion